Motos, Ana
Yang, Hua
Li Bassi, Gianluigi
Yang, Minlan
Meli, Andrea
Battaglini, Denise
Cabrera, Roberto
Bobi, Joaquim
Pagliara, Francesco
Frigola, Gerard
Camprubí-Rimblas, Marta
Fernández-Barat, Laia
Rigol, Montserrat
Ferrer-Segarra, Antoni
Kiarostami, Kasra
Martinez, Daniel
Nicolau, David P.
Artigas, Antonio
Pelosi, Paolo
Vila, Jordi
Torres, Antoni
Funding for this research was provided by:
Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona
Centro de Investigación Biomédica en Red- Enfermedades Respiratorias, Spain (CB06/06/0028)
Fundació la Marató de TV3 (201831-10)
“la Caixa” Foundation (LCF/PR/HR19/52160019)
Bayer
Quality Research Group from Generalitat de Catalunya (SGR/944)
Institució Catalana de Recerca i Estudis Avançats
Article History
Received: 28 December 2022
Accepted: 22 January 2023
First Online: 14 February 2023
Declarations
:
: This study was conducted according to the European guidelines for the Care of Animal Experimentation at the Division of Animal Experimentation, Department of Pulmonary and Critical Care Medicine, Hospital Clínic, Barcelona, Spain. Documented approval from University of Barcelona Institutional Review Board was obtained prior to the study started (number approval 9772).
: Not applicable.
: A. Torres and G. Li Bassi received an unrestrictive grant from Bayer AG (Berlin, Germany) through their affiliated institution. Bayer AG, the manufacturer of inhaled amikacin, provided funds to support this research. Bayer AG had no role in the data collection, data analysis, or data interpretation. Bayer AG reviewed the final manuscript.